Related Experiment Video
Updated: Apr 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Targeting the Pim kinases in multiple myeloma
N A Keane1, M Reidy2, A Natoni2
1Apoptosis Research Centre, National University of Ireland Galway and Department of Haematology, Galway University Hospital, Galway, Ireland.
Multiple myeloma (MM) treatment needs novel strategies. Targeting Pim-2, a kinase upregulated in MM, offers a promising therapeutic avenue by inhibiting cancer cell survival and bone destruction.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple myeloma (MM) is an incurable plasma cell malignancy.
- Novel therapeutic strategies are essential to improve patient survival rates.
- Pim kinases, particularly Pim-2, are overexpressed in hematological malignancies, including MM.
Purpose of the Study:
- To investigate the role of Pim-2 in multiple myeloma pathogenesis.
- To evaluate Pim-2 as a therapeutic target for MM.
- To explore the potential of Pim inhibitors in MM treatment.
Main Methods:
- Analysis of Pim kinase expression in MM.
- Investigation of Pim-2's function in MM cell proliferation and survival.
- Assessment of Pim-2's role in MM-related bone destruction.
- Evaluation of Pim inhibitor activity in MM models.
Main Results:
- Pim-2 is highly expressed in MM and upregulated by the bone marrow microenvironment.
- Pim-2 promotes MM cell proliferation, survival, and bone destruction.
- Pim kinases may also influence malignant cell trafficking, oncogenic signaling, and therapy resistance.
- The Pim inhibitor LGH447 has demonstrated single-agent activity in MM.
Conclusions:
- Pim-2 is a crucial therapeutic target in multiple myeloma.
- Pim inhibition holds promise for improving MM treatment outcomes.
- Combination therapies involving Pim inhibitors may enhance clinical benefit in MM.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...